Bristol Myers Squibb (NYSE:BMY) Issues Quarterly Earnings Results

Bristol Myers Squibb (NYSE:BMY) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.12, FiscalAI reports. The company had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.85 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the business earned $1.80 EPS. Bristol Myers Squibb updated its FY 2026 guidance to 6.050-6.350 EPS.

Here are the key takeaways from Bristol Myers Squibb’s conference call:

• BMS reaffirmed 2026 guidance and said Q1 results are tracking toward the upper end of ranges after $11.5B in revenue and $1.58 EPS, with ~$11B in cash and $1.1B operating cash flow.
• The growth portfolio gained momentum—portfolio sales were up 9% to ~$6.2B with notable product strength (Breyanzi +53%, Reblozyl +15%, Camzyos nearly doubled) and ELIQUIS up ~13%, supporting diversified near-term revenue drivers.
• Significant pipeline and regulatory progress — iberdomide filing accepted with Breakthrough Therapy designation and a PDUFA date of Aug 17, mezigdomide reported positive Phase III interim data, and iza‑bren showed positive Phase III China results while other lifecycle approvals broaden the portfolio.
• Milvexian is a high‑impact late‑stage program (20,500‑patient AFib study) designed for non‑inferiority vs apixaban with superiority testing on bleeding; readouts for AFib and secondary stroke prevention are expected late‑2026 and management projects substantial commercial upside if successful.
• Opdivo revenue declined ~8% (to ~$2.1B), driven mainly by a U.S. wholesaler inventory drawdown and near‑term demand uncertainty, which management says may normalize later in the year.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY traded up $3.16 during midday trading on Thursday, hitting $60.75. The company’s stock had a trading volume of 24,875,941 shares, compared to its average volume of 8,424,049. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The firm’s fifty day moving average price is $59.56 and its 200-day moving average price is $54.48. The firm has a market cap of $124.04 billion, a P/E ratio of 17.61, a P/E/G ratio of 0.17 and a beta of 0.27. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $62.89.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb’s payout ratio is 73.04%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. The trade was a 15.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.05% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Empire Financial Management Company LLC boosted its stake in Bristol Myers Squibb by 3.3% during the 4th quarter. Empire Financial Management Company LLC now owns 6,190 shares of the biopharmaceutical company’s stock valued at $334,000 after purchasing an additional 200 shares during the period. GW&K Investment Management LLC boosted its stake in Bristol Myers Squibb by 16.8% during the 4th quarter. GW&K Investment Management LLC now owns 1,424 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 205 shares during the period. Binnacle Investments Inc boosted its stake in Bristol Myers Squibb by 17.0% during the 2nd quarter. Binnacle Investments Inc now owns 1,801 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 262 shares during the period. Bank of Jackson Hole Trust boosted its stake in Bristol Myers Squibb by 25.5% during the 4th quarter. Bank of Jackson Hole Trust now owns 1,305 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 265 shares during the period. Finally, E Fund Management Co. Ltd. boosted its stake in Bristol Myers Squibb by 2.6% during the 2nd quarter. E Fund Management Co. Ltd. now owns 10,409 shares of the biopharmaceutical company’s stock valued at $482,000 after purchasing an additional 267 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Q1 beats on both sales and profit: BMY reported Q1 revenue of $11.49B and non-GAAP EPS of $1.58, topping estimates and driving the initial rally as investors reward the surprise top-line growth. Why Bristol Myers Squibb Stock Rocked the Market Today
• Positive Sentiment: Management’s Q1 call signaled confidence in the path forward, highlighting growth-portfolio momentum and cost actions that underpin the company’s FY outlook — this reassured investors despite some guidance nuance. Bristol-Myers Squibb Signals Confident Path After Q1 Call
• Positive Sentiment: Sales mix helped results: Reuters and others note better-than-expected performance from Eliquis and newer oncology/blood-disorder drugs, which offset declines in legacy, lower-margin products. That mix lifted margins and contributed to the profit beat. Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales
• Neutral Sentiment: Guidance reiterated but mixed versus consensus: BMY set FY2026 EPS at $6.05–$6.35 and revenue $46.0–$47.5B; the ranges roughly align with Street views but midpoints are slightly under some analysts’ estimates — investors are parsing beats vs. forward expectations. Bristol-Myers Squibb (NYSE:BMY) Exceeds Q1 CY2026 Expectations
• Neutral Sentiment: Street reaction and analyst notes are mixed-to-positive: several outlets highlight continued analyst support for BMY driven by growth portfolio and cost cuts, but some firms trimmed/updated estimates modestly ahead of the print. Do Wall Street Analysts Like Bristol-Myers Squibb Stock?
• Negative Sentiment: Longer-term risk: analysts and industry pieces warn the upcoming Eliquis patent cliff could meaningfully pressure future revenues (estimates of multi‑billion-dollar erosion over several years), a material downside risk investors must weigh despite the near-term beat. Thinning revenues: inside the $14bn Eliquis patent cliff

Analysts Set New Price Targets

Several brokerages have weighed in on BMY. Royal Bank Of Canada began coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price objective for the company. UBS Group reaffirmed a “buy” rating and issued a $70.00 price target on shares of Bristol Myers Squibb in a report on Friday, March 6th. Bank of America decreased their price target on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, April 9th. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Sunday, April 19th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.